Venture Summit West
February 12th, 2014
Silicon Valley
Computer Graphics Generated Image NOT ACTUAL – Based on Codman Device
SUPER BRIEF HISTORY
Leonhardt Ventures founded in 1982. Has since raised $145
million that has been invested in the development of over 28
innovations and companies. 21 direct Leonhardt patents and
over 70 acquired or licensed patents or technologies.
1982-1985 – Built dozens of cardiac cath labs & ICUs
around the world.
1986-1994 – Developed world leadership in polyurethane
balloon cardiovascular catheters.
1995-1998 – Developed world leadership in stent grafts and
percutaneous heart valves.
1999 – 2008 – Developed world clinical leadership in stem
cell repair of damaged heart muscle.
2009 – Launched Leonhardt’s Launchpads Life Science
Incubator.
2008 to 2012 – Developed world leadership in the
development of electrical stimulation for stem cell therapies.
2012 – Launched Cal-X Stars Innovation & Business
Accelerator.
SUPER BRIEF HISTORY
Major Exits
Leonhardt Ventures and
Core Manufacturing Team
Pacesetter Systems $1 billion > Siemans/St. Jude
AVE $4.3 billion > Medtronic (via WorldMed merger)
Minimed $4.3 billion > Medtronic
Advanced Bionics $800 million > Medtronic
World Medical Mfg. Corp. $70 million > AVE
Bioheart $60 million > IPO 2008 (stock price down since)
Note – We in no way attempt to claim full credit.
Market = 50 million+ people in heart
failure. $40 billion +
Magnitude Problem = 25 million about
to die in next 5 years with current
therapies.
Current Pain = No other therapy
regenerates scar tissue back to
muscle.`
OUR SOLUTION =
1. Implantable programmable Stem Cell
& Growth Factor Pump.
+
2. MyoStim Electrical Stimulator.
=
3. HEART SCAR TISSUE CONVERTED
TO BEATING PUMPING MUSCLE
Cost to Produce = $3000
Sell price = $29,000
Gross Profit = $26,000 per unit
Reimbursement = $58,000 for
procedure = to CRT Pacer, less than
LVADs
Total Annual Sales = $9 billion
Proven Team – The Leonhardt and Core
Manufacturing teams have had more
than $15 billion in exits in this space
already.
Track Record = Pacemakers, Insulin
Pump, Cardio Catheters, Stent Graft,
Intravascular Lung Catheter, Pain Pump,
Percuntaneous Heart Valve, Heart
Pumps, Stem Cell Therapies, Stem Cell
Recruiting Heart Pacer, Biological
Pacers, Wireless sensors.
MYOBLAST ENGRAFTMENT POSTTRANSPLANTATION
Human Heart, Proof of Concept
Contractile muscle tissue growing in the scarred portion of the heart following treatment with myoblast
injections.
* Hagege et al., Viability and Differentiation of Autologous Skeletal Myoblast Grafts in Ischemic Cardiomyopathy,
Lancet, Vol. 361, 2003: 491-492
2
Cell
manufacturing
following thigh
muscle biopsy
Injection of skeletal
myoblasts into scar
tissue using
deflecting-tip
catheter
3
1
Scar tissue
following heart
attack
MARVEL Phase II/III Randomized, Double Blinded, Placebo
Controlled – American Heart Journal November 2011
Mean Change in 6-Minute Walk Distance (meters)
p=0.50
n=6
n=7
n=6
BIO-LEONHARDT – TEAMED
WITH CORE MANUFACTURING
LEONHARDT VINEYARDS
ESTABLISHED JANUARY 2000
BIO-LEONHARDT METHOD
Pre-Treat Scar
1. Micro-RNAs (helps converts scar to muscle). 2. Nutrient hydrogel 3. Electrical
stimulation via MyoStim Pacers of San Diego, California (produced at Core
Manufacturing in Los Angeles). 4. Growth factor infusion ie; VEGF, SDF-1,
HGF 5. Granulocyte colony stimulating factor. 6. Endothelial progenitor cells
derived from adipose tissue.
Treat Scar
1. TANAKA cardiac progenitor cells derived from skeletal muscle as developed in
Japan
2. Cardiac stem cells delivered at rim edge of scar.
3. SDF-1 via Ono Pharmaceuticals in Japan.
4. Nutrient hydrogel
5. Electrical stimulation from MyoStim Pacers San Diego.
6. Injection of iPS cells with MicroRNAs.
7. Cardiobridge or Procyrion implantable pump to allow heart to rest during
healing process.
Post Treat Scar
1. Repeat injections of all of the above. 2. Continued electrical
stimulation. 3. Continued delivery of nutrient hydrogel and growth factors.
(1) The Kanno program stimulates angiogenesis (new blood
vessel growth).
(2) The Chachques-Leonhardt program recruits stem cells to
injured heart tissue areas and proliferates them (includes
resident cardiomyocytes).
(3) The Leonhardt-Chachques program differentiates
recruited and/or injected stem cells to beating heart muscle.
(4) The Leonhardt program senses arrhythmia's-fibrillation
and delivers a low voltage pulse to restart a patient's heart
back to a normal beat.
(5) The final program is a standard synchronization-pacing
program.
STIMULATION OF ANGIOGENESIS
Capillary density in rat TA muscles. Number of capillaries was counted in at least 8 different fields, and
capillary density was obtained by calculation of capillary/muscle fiber area.
Investment Opportunity
Valuation = $5 million
Raising Seed Round = $1 million
New investors = 20% Ownership
Amount Invested to Date = *$450,000
Current Investors = Leonhardt
Ventures, Airspeed Equity, Core
Manufacturing LLC
LEONHARDT VENTURE’S
WORLD’S FIRST STEM CELL
RECRUITING BRA
LEOHARDT VENTURES FOUNDED THE
FIRST CONSCIOUS CAPITALISM STOCK
EXCHANGE